The Association between Serum Cytokine and Chemokine Levels and Antiviral Response by Entecavir Treatment in Chronic Hepatitis B Patients
Antiviral Therapy · 2018-04 · 23 (3) · 239-248
DOI: 10.3851/imp3196 ↗Abstract
Background Although nucleoside/nucleotide analogue therapy is thought to suppress chronic hepatitis B (CHB) via regulation of inflammatory cytokines/chemokines, the mechanism is still unclear. In this study, serum cytokine/ chemokine levels were measured in CHB patients treated with entecavir, and the association with antiviral response was analysed. Methods A total of 78 Japanese patients with CHB were enrolled, and serum cytokine/chemokine levels were measured at baseline and at 12, 24 and 48 weeks of entecavir treatment using the MULTIPLEX kit. Results Antiviral response to entecavir treatment was significantly associated with hepatitis B surface antigen (HBsAg) titre and serum interferon-gamma-inducible protein 10 (IP-10) level (12w; P=0.0002; OR=0.020 [95% CI 0.002, 0.156], P=0.003; OR=0.042 [95% CI 0.005, 0.336], respectively). HBe-positive patients whose serum macrophage-derived chemokine (MDC) level was lower (
EUVIMED